Gemcitabine plus cisplatin (GP) versus 5-FU plus cisplatin (FP) as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC): A randomized, open-label, multicenter, phase III trial

6007Background: There are no well-established first-line chemotherapy regimens for recurrent or metastatic (R/M) NPC. Several small phase II trials suggest that GP has promising efficacy and accept...